Drug-induced and iatrogenic infiltrative lung disease

Camus, P.; Bonniaud, Philippe; Fanton, Annlyse; Camus, Clio; Baudaun, Nicolas; Foucher, Pascal

doi:10.1016/j.ccm.2004.05.006

Cited by 179 publications

(122 citation statements)

References 79 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…The reason for this includes the use of chest radiography as a first-line modality in evaluating nonspecific dyspnoea, a modality that is often unable to detect interstitial disease [9,10]. Whereas idiopathic interstitial pneumonias, as classified by the 2002 Consensus of the American Thoracic Society and European Respiratory Society [10,11], tends to show characteristic patterns at HRCT, parenchymal changes produced by pharmaceutical drugs are highly variable and often investigated with surgical lung biopsy [12][13][14][15].…”

Section: Discussionmentioning

confidence: 99%

“…La ragione di questo fenomeno include il ricorso alla radiografia del torace come tecnica di prima scelta nella valutazione di una dispnea non ben specificata che può spesso non individuare una patologia interstiziale [9,10]. Mentre le pneumopatie interstiziali idiopatiche come sono state classificate dal Consensus del 2002 [10,11] dall'ATS e dall'ERS, spesso mostrano dei pattern tipici all'indagine HRCT, i farmaci possono indurre invece delle alterazioni parenchimali altamente variabili, che spesso finiscono alla biopsia chirurgica [12][13][14][15].…”

Section: Discussioneunclassified

See 1 more Smart Citation

Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussioneunclassified

Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Although incidence of pulmonary toxicity seen with antineoplastic agents is increasing, its pathogenesis has not been well understood. Some risk factors were proposed for pulmonary toxicity; age, cumulative dose effect, lung radiotherapy, O 2 treatment and using combination regimens [16,17]. Docetaxel is one of the antineoplastic agents causing pulmonary toxicity.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary toxicity in patients receiving docetaxel chemotherapy

et al. 2009

View full text Add to dashboard Cite

Pulmonary toxicity can rarely be seen with cytotoxic agents. We aimed at investigating the pulmonary toxicity of docetaxel in patients other than lung carcinoma. Forty patients were investigated prospectively. Spirometry, DLCO and high-resolution computed tomography (HRCT) scans were applied to all patients before and 14-21 days after completion of docetaxel. We used a HRCT scoring system that was based on the previous studies. We have seen no pulmonary symptoms that may reflect pulmonary toxicity. There were statistically significant differences between pre- and post-treatment values of FEV1 (L/s), FEV1/FVC (%), DLCO/VA (DLCO/L), DLCO/VA (%) (P<0.05), FEF25-75 (L/s), FEF25-75 (%) (P<0.01), DLCO (mL/mmHg/min), DLCO (%) (P<0.001), Also, there was a statistically significant difference between the pre- and post-treatment HRCT scores. There was a statistical relationship between post-treatment HRCT scores, number of docetaxel cycles (r=0.49, P<0.0001) and docetaxel cumulative dose (r=0.61, P<0.0001). Docetaxel caused a significant decline in pulmonary function tests (PFTs) and progression in HRCT scores but the symptoms of patients were not consistent with these differences. The negative effects of docetaxel on PFTs and HRCT scores should be investigated more reliably by increasing the number of patients with further studies.

show abstract

“…Die histologischen Muster medikamenteninduzierter Lungenparenchymreaktionen sind variabel und im allgemeinen unspezifisch [5,17,18].Die BAL ergab die Diagnose einer eosinophilen Alveolitis mit einer deutlichen Eosinophilie von 20%. Zusätzlich konnte auch in der Schleimhaut der Atemwege histologisch eine starke Gewebseosinophilie nachgewiesen werden.…”

Section: Bakteriologie Desunclassified

Pulmonale Infiltrate mit Bluteosinophilie bei einer 62-j�hrigen Patientin

et al. 2003

View full text Add to dashboard Cite

A 62-year-old woman was admitted because of chronic cough and bilateral infiltrates on chest roentgenogram. Additional history revealed that the patient had been taken diclofenac emulgel during the previous 10 years for arthrosis. Diagnostic bronchoscopy showed eosinophilic alveolitis. After ruling out infectious, parasitic or systemic diseases drug-induced eosinophilic pneumonia was diagnosed due to topical diclofenac therapy and subsequent percutaneous drug absorption. No previous case of eosinophilic pneumonia to topical diclofenac was discovered in our review of the literature. The diclofenac therapy was discontinued. Oral corticosteroid therapy cleared bilateral infiltrates on CT scan within seven days. Drug reactions are the most common cause of pulmonary infiltrates with blood eosinophilia and/or eosinophilic alveolitis and should be considered as a differential diagnosis.

show abstract

Drug-induced and iatrogenic infiltrative lung disease

Cited by 179 publications

References 79 publications

Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy

Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy

Pulmonary toxicity in patients receiving docetaxel chemotherapy

Pulmonale Infiltrate mit Bluteosinophilie bei einer 62-j�hrigen Patientin

Contact Info

Product

Resources

About